OakChart

Bullfrog AI Holdings Inc

BFRGHealthcare·Health Information Services·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.5801-0.0189 (-3.16%)
2026-11-12 02:27 CET
Market cap
10.76 USD m
Revenue, TTM
0.30 USD m
Net income, TTM
-6.00 USD m
Free cash flow, TTM
-5.50 USD m
EPS diluted, TTM
-0.48
P/E
-
Compare

Price

BFRG against its 20, 50 and 200-day averages
2050200earnings
0.400.600.801.0095.9M191.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BFRGclose 0.5820-day 0.5150-day 0.55200-day 0.650.5852w low

70.4% under the 52-week high of 1.96 on 31 Mar 2026. 52-week low 0.43 on 12 Feb 2026. Last 15 sessions, 30.4% high to low

Volume 0.04× normal · the line is the 50-bar volume average

Profile

BFRG
52-week range, 10% of the way up
0.431.96

BullFrog AI Holdings, Inc. is a digital biopharmaceutical company, which engages in artificial intelligence and machine learning driven analysis of complex data sets in medicine and healthcare. The company was founded by Vininder Singh in August 2017 and is headquartered in Gaithersburg, MD.

Employees9
IPOFeb 14, 2023
Beta-2.68
ATR, 14d0.05
Rel volume0.04
Short float4.70%
Insider own13.60%
Inst own6.04%

Snapshot

6 groups

Valuation

Index-
Market Cap10.76M
Enterprise Value3.93M
Income-6.00M
Sales0.30M
Book/sh0.38
Cash/sh0.37
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees9
IPOFeb 14, 2023

Ratios

P/E-
Forward P/E-
PEG-
P/S35.86
P/B1.54
P/C1.55
P/FCF-
EV/EBITDA-
EV/Sales13.10
Quick Ratio10.57
Current Ratio10.57
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.48
EPS next Y-
EPS next Q-0.09
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-10.94% -59.71%
Sales past 3/5Y126.81% -
EPS Y/Y TTM38.11%
Sales Y/Y TTM798.45%
EPS Q/Q51.17%
Sales Q/Q547.64%
EarningsSep 02
EPS/Sales Surpr.0.00% 0.00%

Ownership

Insider Own13.60%
Insider Trans5.22%
Inst Own6.04%
Inst Trans9.13%
ROA-113.54%
ROE-130.71%
ROIC-85.82%
Gross Margin40.34%
Oper. Margin-2042.19%
Profit Margin-2006.87%
SMA2012.70%
SMA504.96%
SMA200-10.12%
Trades-

Technical

Shs Outstand18.54M
Shs Float16.02M
Short Float4.70%
Short Ratio0.14
Short Interest0.75M
52W High1.96 -70.40%
52W Low0.43 36.46%
Volatility10.29% 8.29%
ATR (14)0.05
RSI (14)55.68
Beta-2.68
Rel Volume0.04
Avg Volume5.29M
Volume228,649

Performance

Perf Week10.22%
Perf Month1.97%
Perf Quarter-1.84%
Perf Half Y-7.92%
Perf YTD-34.29%
Perf Year-46.78%
Perf 3Y-80.07%
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close0.60
Price0.58
Change %-3.16%

Peers

Mkt cap
TickerCompanyMkt cap
LTRNLantern Pharma Inc7.19M
SDGRSchrodinger Inc2.37B
HYFTMindWalk Holdings Corp49.00M
CERTCertara Inc1.79B
RXRXRecursion Pharmaceuticals Inc2.24B
ONMDOneMedNet Corp32.28M
EVAXEvaxion A/S ADR24.27M
ABSIAbsci Corp1.74B
KTTAPasithea Therapeutics Corp17.77M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Blacher JoshuaChief Financial OfficerSep 22 '26Buy0.5350,00026,42565,000Sep 22 04:46 PM
Singh VininderChief Executive OfficerSep 22 '26Buy0.6075,00044,9182,442,446Sep 22 04:45 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • BullFrog AI Founder and CEO Vin Singh to Deliver Keynote at AIDDD Summit (GlobeNewswire)
  • BullFrog AI to Present at the 20th Annual LD Micro Main Event on October 20, 2026 (GlobeNewswire)
  • BullFrog AI Advances Major Depressive Disorder Drug Discovery Program With Global Pharma Partner (InvestorsHub) +15.99%
  • BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder (GlobeNewswire)
  • BullFrog AI to Participate in September 2026 Investor Conferences (GlobeNewswire)
  • iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026 (ACCESSWIRE)
  • BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire) -5.28%
  • BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026 (GlobeNewswire)
  • BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform (GlobeNewswire) +9.59%
  • BullFrog AI Regains Compliance with Nasdaq Shareholders' Equity Requirement (GlobeNewswire) -6.50%
  • BullFrog AI Announces Participation at AACR Annual Meeting (GlobeNewswire)
  • BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners (GlobeNewswire) +18.55%
  • BC-Most Active Stocks (Associated Press) +60.00%
  • BC-Most Active Stocks (Associated Press) +106.57%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-0.070-0.070-0.220.221
2026Q12026-06-03-0.120--0.00--
2026Q3---0.090--0.221
2026Q4---0.100--0.351
2027Q1---0.050--0.751
2027Q2---0.050--0.751
2027Q3---0.030--1.751
2027Q4---0.030--2.001
2028Q1---0.010--3.001
2028Q2--0.000--3.501
2028Q3--0.010--4.001
2028Q4--0.020--5.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-021000.220.220.22
2026Q3S2026-08-171000.220.220.22
2026Q3E2026-10-31100-0.09-0.09-0.09
2026Q3E2026-09-02110-0.09-0.09-0.09
2026Q3E2026-08-17110-0.09-0.09-0.09
2026Q3E2026-06-23100-0.11-0.11-0.11
2026Q2S2026-08-171000.220.220.22
2026Q2E2026-08-17110-0.07-0.07-0.07
2026Q2E2026-06-23100-0.11-0.11-0.11

Estimate history

EPS, annual-0.061-0.104-0.46-0.885-0.854-0.629-0.4751
Period202020212022202320242025TTM
EPS, quarterly-0.198-0.217-0.193-0.208-0.149-0.15-0.13-0.123-0.073
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual000.010.06500.1170.3
Period202020212022202320242025TTM
Sales, quarterly00000.0330.083000.215
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual5.655.656.0876.0959.11311.41818.542
Period202020212022202320242025MRQ
Shares, quarterly7.8517.8519.1139.4169.62710.41711.41818.44718.542
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.300.120.000.070.010.000.00
Cost of Goods Sold Incl. D&A0.180.100.000.010.550.000.00
Gross Profit0.120.02-0.000.06-0.540.000.00
Selling, General and Administrative Excl. Other6.226.617.235.431.920.560.35
Research and Development1.521.802.221.430.61--
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-6.10-6.59-7.24-5.37-2.46-0.56-0.35
Interest Expense0.010.010.020.080.350.040.01
Unusual Expense0.000.000.000.090.00-0.01-0.02
Net Income Before Taxes-6.00-6.50-6.99-5.36-2.80-0.59-0.34
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-6.00-6.50-6.99-5.36-2.80-0.59-0.34
Net Income From Continuing Operations-6.00-6.50-6.99-5.36-2.80-0.59-0.34
Net Income-6.00-6.50-7.04-5.36-2.80-0.59-0.34
EPS (Recurring)-0.32-0.63-0.85-0.87-0.46-0.10-0.06
EPS (Basic, Before Extraordinaries)-0.48-0.63-0.85-0.89-0.46-0.10-0.06
EPS (Diluted)-0.48-0.63-0.85-0.89-0.46-0.10-0.06
EBITDA-6.10-6.59-7.23-5.37-2.45-0.56-0.35
Non-Operating Income (Expense)0.110.100.260.180.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense0.771.010.940.630.340.100.09
Price To Sales Ratio44.6978.22-303.42---
Gross Margin40.3417.29-89.35-5,396.94--
Operating Margin-2,042.19-5,652.38--8,257.73-24,558.01--
Net Margin-2,006.87-5,569.61--8,239.80-28,024.87--
Shares Outstanding18.5411.429.116.096.095.655.65
Market Capitalization10.7611.1117.4319.8719.87--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.220.000.000.080.030.000.000.00
Cost of Goods Sold Incl. D&A0.110.000.000.070.030.000.000.00
Gross Profit0.11-0.00-0.000.010.01-0.00-0.00-0.00
Selling, General and Administrative Excl. Other1.531.611.501.581.482.061.771.82
Research and Development0.340.430.400.350.480.580.590.57
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.42-1.61-1.50-1.57-1.47-2.06-1.77-1.82
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-1.37-1.59-1.48-1.55-1.45-2.02-1.71-1.76
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.37-1.59-1.48-1.55-1.45-2.02-1.71-1.76
Net Income From Continuing Operations-1.37-1.59-1.48-1.55-1.45-2.02-1.71-1.76
Net Income-1.37-1.59-1.48-1.55-1.45-2.02-1.76-1.76
EPS (Recurring)-0.07-0.12-0.13-0.15-0.15-0.21-0.19-0.22
EPS (Basic, Before Extraordinaries)-0.07-0.12-0.13-0.15-0.15-0.21-0.19-0.22
EPS (Diluted)-0.07-0.12-0.13-0.15-0.15-0.21-0.19-0.22
EBITDA-1.42-1.61-1.50-1.57-1.47-2.06-1.77-1.82
Non-Operating Income (Expense)0.050.020.020.020.020.040.060.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.110.130.150.380.180.300.210.20
Price To Sales Ratio44.69186.4686.40124.55440.71---
Gross Margin49.43--17.9118.31---
Operating Margin-658.85---1,881.82-4,419.14---
Net Margin-636.78---1,860.16-4,356.16---
Shares Outstanding18.5418.4511.4210.429.639.429.117.85
Market Capitalization11.1121.2810.0714.1114.2215.5417.4322.53

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments2.185.442.620.060.010.01
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.400.110.150.010.000.00
Total Current Assets2.585.552.770.070.010.01
Net Property, Plant & Equipment0.000.000.010.010.000.00
Total Investments and Advances0.220.000.000.000.000.00
Long-Term Note Receivable----0.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets0.00-----
Other Assets0.000.000.000.000.000.00
Total Assets2.815.552.780.080.010.01
Short Term Debt Incl. Current Port. of LT Debt0.000.000.001.580.590.21
Accounts Payable0.170.440.100.540.000.00
Other Current Liabilities0.500.150.081.010.430.34
Total Current Liabilities0.670.590.183.141.020.55
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.00-----
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.670.590.183.141.020.55
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value1E-061E-061E-061E-060.000.00
Common Equity2.144.962.59-3.06-1.01-0.54
Total Shareholders Equity2.144.962.59-3.06-1.01-0.54
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity2.144.962.59-3.06-1.01-0.54
Total Liabilities & Stockholders Equity2.815.552.780.080.010.01
Book Value Per Share0.190.540.43-0.50-0.18-0.10
Tangible Book Value Per Share0.190.540.43-0.50-0.18-0.10
Full-Time Employees9944--
Price to Book Ratio1.594.115.275.27--
Return on Assets-155.45-167.95-374.94-6,201.36-7,742.55-
Return on Equity-183.04-185.12----
Return on Invested Capital-304.17-140.89-206.61---
Quick Ratio3.859.4315.030.020.010.01
Current Ratio3.859.4315.030.020.010.01

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-6.00-6.50-6.99-5.36-2.80-0.59-0.34
Depreciation0.000.000.000.000.00--
Other Funds (Non Cash)0.650.890.940.790.750.110.07
Funds from Operations-5.34-5.60-6.05-4.56-2.05-0.48-0.27
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-0.160.080.44-1.441.140.100.06
Cash from Operating Activities-5.50-5.52-5.61-6.00-0.91-0.38-0.21
Capital Expenditures0.000.000.000.00-0.010.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.00-0.010.000.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock9.962.378.428.790.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock9.962.378.428.790.000.000.00
Proceedsfrom Stock Options9.962.378.328.790.000.000.00
Issuance or Reduction of Debt, Net-0.020.000.00-0.220.970.390.21
Change in Long Term Debt0.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.00
Cash from Financing Activities9.942.378.428.570.970.390.21
Net Change in Cash4.44-3.152.812.570.050.00-0.00
Free Cash Flow-5.50-5.52-5.61-6.00-0.92-0.38-0.21
Preferred Dividends (Cash Flow)-----0.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments6.925.082.181.992.473.80
Short Term Receivables0.220.000.000.060.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.340.230.400.490.230.28
Total Current Assets7.475.322.582.542.704.08
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.220.220.220.160.160.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets--0.00---
Other Assets0.000.000.000.000.000.00
Total Assets7.695.542.812.702.874.09
Short Term Debt Incl. Current Port. of LT Debt0.090.130.000.060.110.16
Accounts Payable0.170.220.170.170.180.21
Other Current Liabilities0.450.300.500.530.390.46
Total Current Liabilities0.710.650.670.760.680.84
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.00---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.710.650.670.760.680.84
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value1E-061E-061E-061E-061E-061E-06
Common Equity6.994.892.141.942.193.25
Total Shareholders Equity6.994.892.141.942.193.25
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity6.994.892.141.942.193.25
Total Liabilities & Stockholders Equity7.695.542.812.702.874.09
Book Value Per Share0.380.260.190.190.230.34
Tangible Book Value Per Share0.380.260.190.190.230.34
Full-Time Employees--9---
Price to Book Ratio1.598.984.736.164.383.03
Return on Assets-113.54-126.21-155.45-184.34-155.26-121.13
Return on Equity-130.71-149.35-183.04-233.50-183.40-141.43
Return on Invested Capital-19.63-32.60-69.29-79.83-66.21-62.15
Quick Ratio10.578.153.853.343.974.86
Current Ratio10.578.153.853.343.974.86

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.37-1.59-1.48-1.55-1.45-2.02
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)0.110.130.040.380.180.30
Funds from Operations-1.26-1.47-1.44-1.17-1.27-1.72
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.25-0.230.260.07-0.16-0.08
Cash from Operating Activities-1.51-1.69-1.18-1.11-1.43-1.80
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.00--
Change in Capital Stock3.394.461.430.680.260.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.394.461.430.680.260.00
Proceedsfrom Stock Options3.394.461.430.680.260.00
Issuance or Reduction of Debt, Net-0.040.13-0.06-0.05-0.050.16
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.354.591.380.620.210.16
Net Change in Cash1.842.900.19-0.48-1.22-1.63
Free Cash Flow-1.51-1.69-1.19-1.11-1.43-1.80

Revenue breakdown

Pharmaceutical Preparations2025: 116.67K
United States2025: 116.67K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.70%0.8M16.0M5.29M
2026-10-156.31%1.0M16.0M5.29M
2026-09-304.61%0.7M16.0M4.33M
2026-09-150.63%0.1M16.2M137.26K
2026-08-310.58%0.1M16.2M166.09K
2026-08-140.60%0.1M16.2M210.82K
2026-07-310.66%0.1M16.2M239.24K
2026-07-150.74%0.1M16.2M363.21K
2026-06-301.43%0.2M16.2M4.67M
2026-06-152.47%0.4M16.2M11.11M
2026-05-293.48%0.6M16.1M11.27M
2026-05-154.49%0.7M15.3M11.27M
2026-04-305.09%0.7M13.8M11.44M
2026-04-1511.28%1.6M13.8M11.52M
2026-03-3164.26%5.9M9.1M10.75M
2026-03-136.04%0.6M9.1M664.67K
2026-02-277.88%0.6M8.2M640.57K
2026-02-137.14%0.6M8.2M591.72K
2026-01-306.64%0.5M8.2M576.11K
2026-01-157.41%0.6M8.2M554.15K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-224Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-08-208-KCurrent report2026-08-18SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-06424B3SEC
2026-06-158-KCurrent report2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-10EFFECTEffectiveness filing by commission orderSEC
2026-06-08CORRESPSEC
2026-06-04UPLOADUpload SubmissionSEC
2026-05-29S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-01DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-30SEC
2026-04-228-KCurrent report2026-04-22SEC
2026-04-218-KCurrent report2026-04-15SEC
2026-04-138-KCurrent report2026-04-13SEC
2026-04-01424B5SEC
2026-04-018-KCurrent report2026-03-31SEC
2026-03-308-KCurrent report2026-03-27SEC
2026-03-1910-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-238-KCurrent report2026-02-19SEC
2026-02-178-KCurrent report2026-02-10SEC
2025-12-308-KCurrent report2025-12-30SEC
2025-12-01424B3SEC
2025-11-25EFFECTEffectiveness filing by commission orderSEC
2025-11-24CORRESPSEC
2025-11-1410-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0971.34K200
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITADEL ADVISORS LLC1.95%
J. Safra Sarasin Holding AG0.61%
VANGUARD FIDUCIARY TRUST CO0.57%
GEODE CAPITAL MANAGEMENT, LLC0.56%
VANGUARD CAPITAL MANAGEMENT LLC0.49%
Vontobel Holding Ltd.0.38%
JANE STREET GROUP, LLC0.36%
FORTEM FINANCIAL GROUP, LLC0.27%
RAYMOND JAMES FINANCIAL INC0.24%
ACT Advisors, LLC.0.20%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.46%
VANGUARD EXTENDED MARKET INDEX FUND0.37%
Fidelity Series Total Market Index Fund0.04%
Fidelity Total Market Index Fund0.04%
Fidelity Nasdaq Composite Index Fund0.02%

OakChart. BFRG. Cached 15 minutes.

Some panels did not load: ratings.